Novavax, Inc.’s proposed COVID-19 vaccine showed strong efficacy against older variants, but the US Food and Drug Administration now wonders how it will perform against the current virus strain.
The company is seeking an emergency use authorization for a two-dose primary series of its adjuvanted recombinant spike protein
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?